These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 14565788)

  • 41. Chemotherapy with or without gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of 6,844 patients.
    Zhou H; Zeng C; Wang LY; Xie H; Zhou J; Diao P; Yao WX; Zhao X; Wei Y
    Chin Med J (Engl); 2013; 126(17):3348-55. PubMed ID: 24033963
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New directions in oncology nursing care: focus on gefitinib in patients with lung cancer.
    Pizzo B
    Clin J Oncol Nurs; 2004 Aug; 8(4):385-92. PubMed ID: 15354925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?
    Rukazenkov Y; Speake G; Marshall G; Anderton J; Davies BR; Wilkinson RW; Mark Hickinson D; Swaisland A
    Anticancer Drugs; 2009 Nov; 20(10):856-66. PubMed ID: 19657272
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania.
    Veronese ML; Algazy K; Bearn L; Eaby B; Alavi J; Evans T; Stevenson JP; Shults J
    Cancer Invest; 2005; 23(4):296-302. PubMed ID: 16100941
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: a meta-analysis from randomized controlled clinical trials.
    Zhao YL; Han S; Pu R; Shi LW
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e86-91. PubMed ID: 25818741
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer.
    Forsythe B; Faulkner K
    Drug Saf; 2004; 27(14):1081-92. PubMed ID: 15554744
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example.
    Li-Wan-Po A; Farndon PA; Kobayashi S; Mitsudomi T; Potter VA
    Ann Pharmacother; 2011 Feb; 45(2):263-75. PubMed ID: 21304034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gefitinib.
    Culy CR; Faulds D
    Drugs; 2002; 62(15):2237-48; discussion 2249-50. PubMed ID: 12381224
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer.
    Frampton JE; Easthope SE
    Drugs; 2004; 64(21):2475-92. PubMed ID: 15482004
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer.
    Cersosimo RJ
    Am J Health Syst Pharm; 2004 May; 61(9):889-98. PubMed ID: 15156965
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer.
    Kim JH; Kim HS; Choi JS; Lee KM; Shin YC; Ahn BM; Choi DR; Kwon JH; Park S; Kim HY; Jung JY; Kim HJ; Song HH; Zang DY
    Lung Cancer; 2009 Apr; 64(1):121-3. PubMed ID: 19022521
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gefitinib (Iressa) for advanced non-small cell lung cancer.
    Med Lett Drugs Ther; 2002 Sep; 44(1138):77-8. PubMed ID: 12205428
    [No Abstract]   [Full Text] [Related]  

  • 53. ZD1839 (Iressa) in non-small cell lung cancer.
    Herbst RS; Kies MS
    Oncologist; 2002; 7 Suppl 4():9-15. PubMed ID: 12202783
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gefitinib: current status in the treatment of non-small cell lung cancer.
    Tanović A; Alfaro V
    Drugs Today (Barc); 2004 Oct; 40(10):809-27. PubMed ID: 15605116
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.
    Horgan AM; Bradbury PA; Amir E; Ng R; Douillard JY; Kim ES; Shepherd FA; Leighl NB
    Ann Oncol; 2011 Aug; 22(8):1805-11. PubMed ID: 21273345
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A severe dermatologic adverse effect related with gefitinib: case report and review of the literature.
    Li YQ; Sun H; Xue D
    J Cancer Res Ther; 2013 Sep; 9 Suppl 2():S110-3. PubMed ID: 24135241
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis.
    Chang CH; Chen KY; Young-Xu Y; Kurth T; Orav EJ; Yang PC; Chan KA
    Lung Cancer; 2008 Nov; 62(2):242-52. PubMed ID: 18423782
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gefitinib.
    Rahman AF; Korashy HM; Kassem MG
    Profiles Drug Subst Excip Relat Methodol; 2014; 39():239-64. PubMed ID: 24794908
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer.
    Natale RB
    Semin Oncol; 2004 Jun; 31(3 Suppl 9):23-30. PubMed ID: 15206079
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gefitinib: phase II and III results in advanced non-small cell lung cancer.
    Kelly K; Averbuch S
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):93-9. PubMed ID: 14981586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.